Lucid/PAVmed cut 20% workforce, delay studies, halt products to reduce cash burn 25%

Lucid Diagnostics Inc.

Workforce reduction of ~20% and other cost cuts aimed at lowering quarterly cash burn by at least 25%.
Delays completion of EsoGuard BE-2 study to H2 2023; pauses EsoCure Esophageal Ablation device development.
Maintains ~40 sales staff and nurse practitioners; shifts focus to large institutional accounts and satellite LTC program.
PAVmed indefinitely pauses CarpX, PortIO, NextFlo product development; suspends annual cash bonuses.
Veris Health delays implantable physiologic monitor development to H2 2023; prioritizes Cancer Care Platform adoption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.